Condition: Melanoma · In-Transit Metastasis · Sponsor: Vastra Gotaland Region
To evaluate safety and the effect of isolated limb perfusion together with nivolumab as a way to increase efficacy and give further insights in early immunological mechanisms. In the first phase Ib part, 20 patients will be enrolled and followed for a minimum of 3 months. An independent data safety monitoring board (DSMB) will continuously review safety and judge the seriousness of the events and also recommend the study to stop if necessary. If the DSMB do not find safety issues, the trial will continue as a phase II trial.
This description comes directly from the study's public registry record.
Roger Olofsson Bagge, MD, PhD · +46 31 3428207 · roger.olofsson.bagge@gu.se
Therese Bengtsson · +46 31 3420000 · therese.bengtsson@vgregion.se
Always discuss trial participation with your own doctor first.
| Netherlands Cancer Institute | Amsterdam, Netherlands | Recruiting |
| Erasmus MC Cancer Institute | Groningen, Netherlands | Not Yet Recruiting |
| Erasmus MC Cancer Institute | Rotterdam, Netherlands | Not Yet Recruiting |
| Sahlgrenska University Hospital | Gothenburg, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03685890